List of Kuano AI Customers
Cambridge, CB22 5HX,
United Kingdom
Since 2010, our global team of researchers has been studying Kuano AI customers around the world, aggregating massive amounts of data points that form the basis of our forecast assumptions and perhaps the rise and fall of certain vendors and their products on a quarterly basis.
Each quarter our research team identifies companies that have purchased Kuano AI for ML and Data Science Platforms from public (Press Releases, Customer References, Testimonials, Case Studies and Success Stories) and proprietary sources, including the customer size, industry, location, implementation status, partner involvement, LOB Key Stakeholders and related IT decision-makers contact details.
Companies using Kuano AI for ML and Data Science Platforms include: University of Bristol, a United Kingdom based Education organisation with 8369 employees and revenues of $1.21 billion, Alzheimer's Research UK, a United Kingdom based Non Profit organisation with 244 employees and revenues of $72.0 million, Kuano, a United Kingdom based Professional Services organisation with 20 employees and revenues of $1.0 million, Onco-Innovations Canada, a Canada based Life Sciences organisation with 10 employees and revenues of $1.0 million and many others.
Contact us if you need a completed and verified list of companies using Kuano AI, including the breakdown by industry (21 Verticals), Geography (Region, Country, State, City), Company Size (Revenue, Employees, Asset) and related IT Decision Makers, Key Stakeholders, business and technology executives responsible for the software purchases.
The Kuano AI customer wins are being incorporated in our Enterprise Applications Buyer Insight and Technographics Customer Database which has over 100 data fields that detail company usage of software systems and their digital transformation initiatives. Apps Run The World wants to become your No. 1 technographic data source!
Apply Filters For Customers
| Logo | Customer | Industry | Empl. | Revenue | Country | Vendor | Application | Category | When | SI | Insight |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
Alzheimer's Research UK | Non Profit | 244 | $72M | United Kingdom | Kuano | Kuano AI | ML and Data Science Platforms | 2021 | n/a |
In 2021, Alzheimer's Research UK implemented Kuano AI in a research collaboration with the UCL Drug Discovery Institute to identify NOTUM enzyme inhibitors in the United Kingdom. Kuano AI was deployed as an ML and Data Science Platforms solution to support drug discovery and research and development functions at the institute, linking computational design to experimental validation workflows.
The implementation focused on Kuano AI transition-state quantum simulation and AI-driven hit-generation modules described in the Kuano announcement. Configuration and usage centered on in silico quantum transition-state modelling combined with machine learning guided hit generation to produce prioritized chemical candidates for testing, aligning Kuano AI with cheminformatics, virtual screening, and hit prioritization workflows common to ML and Data Science Platforms.
Operational integration routed Kuano AI outputs to the UCL Drug Discovery Institute for experimental testing and validation, creating an in silico to in vitro handoff under the research collaboration. Governance and process responsibilities were split between Alzheimer's Research UK coordinating computational study scope and the DDI executing experimental assays, establishing Kuano AI as a computational R&D tool within the organization’s research technology stack.
|
|
|
Kuano | Professional Services | 20 | $1M | United Kingdom | Kuano | Kuano AI | ML and Data Science Platforms | 2024 | n/a |
In 2024, Kuano implemented Kuano AI within the ML and Data Science Platforms category to formalize its data science and model delivery capabilities for its professional services business. The deployment is cloud native and uses containerized model runtimes with a centralized model registry to support development through production workflows and reproducible pipelines.
Kuano AI is configured with core modules typical of ML and Data Science Platforms, including experiment tracking, feature engineering and data pipeline orchestration, a model registry, deployment orchestration and inference endpoints, and monitoring for model performance and data drift. Operational coverage centers on data science, consulting and product teams, centralizing dataset access and enforcing role based governance through model versioning and approval workflows, while integrating with continuous integration practices for pipeline testing and model promotion.
|
 |
Onco-Innovations Canada | Life Sciences | 10 | $1M | Canada | Kuano | Kuano AI | ML and Data Science Platforms | 2025 | n/a |
In 2025 Onco-Innovations Canada engaged Kuano AI in a pilot collaboration to apply a quantum enabled AI platform to accelerate design and optimisation of PNKP inhibitors for drug discovery and R&D in Canada. The Kuano AI deployment is positioned within ML and Data Science Platforms and targets delivery of structural binding models, validated platform outputs and candidate compound designs as stated in the collaboration announcement.
The implementation focuses on Kuano AI functional capabilities, inferred from the press release to include Kuano quantum molecular modelling branded Quantum Lens and generative AI compound design capabilities. Configuration indicates an emphasis on quantum molecular modelling for binding prediction, generative compound enumeration for candidate design, and a validation pipeline to produce platform verified structural models suitable for experimental follow up.
Operational scope for the pilot is concentrated in Onco-Innovations research and development workflows, specifically computational chemistry and medicinal chemistry decision processes supporting PNKP inhibitor technology development. The collaboration frames outputs from Kuano AI as inputs to experimental validation and candidate triage rather than production manufacturing or clinical systems.
Governance for the pilot is organized around iterative validation cycles, model output review by cross functional scientific teams, and defined acceptance criteria for candidate designs prior to laboratory testing. The engagement is described as a research mode pilot with future expansion contingent on validation outcomes and platform performance.
|
 |
|
Education | 8369 | $1.2B | United Kingdom | Kuano | Kuano AI | ML and Data Science Platforms | 2025 | n/a |
|
Buyer Intent: Companies Evaluating Kuano AI
Discover Software Buyers actively Evaluating Enterprise Applications
| Logo | Company | Industry | Employees | Revenue | Country | Evaluated | ||
|---|---|---|---|---|---|---|---|---|
| No data found | ||||||||